Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study.
Schettini F, Saracchini S, Bassini A, Marus W, Corsetti S, Specogna I, Bertola M, Micheli E, Wirtz RM, Laible M, Şahin U, Strina C, Milani M, Aguggini S, Tancredi R, Fiorio E, Sulfaro S, Generali D. Schettini F, et al. Among authors: strina c. Breast. 2024 Aug;76:103753. doi: 10.1016/j.breast.2024.103753. Epub 2024 May 25. Breast. 2024. PMID: 38815444 Free PMC article.
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, Rangoni G, Grisanti S, Tiberio GA, Nodari F, Strina C, Marini G. Ferrari V, et al. Among authors: strina c. Cancer Chemother Pharmacol. 2006 Jan;57(2):185-90. doi: 10.1007/s00280-005-0028-1. Epub 2005 Sep 3. Cancer Chemother Pharmacol. 2006. PMID: 16151811 Clinical Trial.
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, Bottini A, Berruti A, Generali D. Allevi G, et al. Among authors: strina c. Br J Cancer. 2013 Apr 30;108(8):1587-92. doi: 10.1038/bjc.2013.151. Epub 2013 Apr 11. Br J Cancer. 2013. PMID: 23579222 Free PMC article. Clinical Trial.
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, Pritzker L, Pritzker K, Parissenti A, Santini D, Fox SB, Bottini A, Generali D. Foroni C, et al. Among authors: strina c. Breast Cancer Res Treat. 2014 Feb;144(1):113-21. doi: 10.1007/s10549-014-2840-y. Epub 2014 Jan 28. Breast Cancer Res Treat. 2014. PMID: 24469643 Clinical Trial.
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.
Koukourakis MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, Ferrozzi F, Harris AL, Generali D. Koukourakis MI, et al. Among authors: strina c. Br J Cancer. 2014 Apr 29;110(9):2209-16. doi: 10.1038/bjc.2014.196. Epub 2014 Apr 10. Br J Cancer. 2014. PMID: 24722179 Free PMC article.
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, Petronini PG, Fox SB, Harris AL, Martinotti M, Berruti A, Bottini A, Reynolds AR, Generali D. Bazzola L, et al. Among authors: strina c. Br J Cancer. 2015 Jan 6;112(1):52-60. doi: 10.1038/bjc.2014.563. Epub 2014 Dec 2. Br J Cancer. 2015. PMID: 25461806 Free PMC article.
Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A. Generali D, et al. Among authors: strina c. J Natl Cancer Inst Monogr. 2015 May;2015(51):32-5. doi: 10.1093/jncimonographs/lgv019. J Natl Cancer Inst Monogr. 2015. PMID: 26063883
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, Bottini A, Harris AL, Fox SB. Generali D, et al. Among authors: strina c. J Natl Cancer Inst Monogr. 2015 May;2015(51):64-6. doi: 10.1093/jncimonographs/lgv018. J Natl Cancer Inst Monogr. 2015. PMID: 26063890 Clinical Trial.
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D. Roviello G, et al. Among authors: strina c. Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21. Future Oncol. 2016. PMID: 27324108 Clinical Trial.
35 results